Revisiting 'Off-Label' Drug Promotion Resolutions in Light of 'Caronia'

, New York Law Journal


Peter G. Neiman, Seth B. Orkand and Peter K. Vigeland of WilmerHale write that although the Second Circuit's recent decision in 'Caronia' addressed a prosecution based only on truthful speech by a pharmaceutical sales representative, the logic of the decision would seem to reach more broadly, calling into question the government's theory underlying many prior off-label promotion cases which had resulted in large criminal fines, forfeitures, and related civil settlements.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Continue to Lexis Advance®

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202590083223

Thank you!

This article's comments will be reviewed.